CN1548525A - Recombinant yeast strain and IFN alpha-la interferon purifying process - Google Patents
Recombinant yeast strain and IFN alpha-la interferon purifying process Download PDFInfo
- Publication number
- CN1548525A CN1548525A CNA021089736A CN02108973A CN1548525A CN 1548525 A CN1548525 A CN 1548525A CN A021089736 A CNA021089736 A CN A021089736A CN 02108973 A CN02108973 A CN 02108973A CN 1548525 A CN1548525 A CN 1548525A
- Authority
- CN
- China
- Prior art keywords
- interferon
- rabbit
- pgapz
- collect
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to the key technology and result of constructing engineering yeast strain IFN alpha-1a/pGAPZ alpha-A/GS115 secreting alpha-1a interferon and the purification process of produced interferon. The present invention adopts yeast secretion expressing system, rather than traditional colibacillus inclusion body expression system, and the target protein alpha-1a interferon has no needs of renaturation, biological specific activity of 1.0E9 unit/mg protein and low toxic side effect. The purification process can obtain target protein alpha-1a interferon of 95 % purity without needing expensive monoclonal antibody column for lowering production cost.
Description
[technical field]
The present invention relates to the engineering strain of secreting, expressing α-1a Interferon, rabbit and utilize it to produce the purification process of α-1a Interferon, rabbit.
[background technology]
At present, the α of domestic production-1a Interferon, rabbit mostly is e. coli expression product, and the main technique defective is: colibacillary expression system needs renaturation for comprising build in the production process, renaturation yield is low, is up to 40%, thereby specific activity is low, has only 1.0 * 10
8There is bigger side effect in unit/milligram albumen; And, will be in the separation and purification with being worth expensive monoclonal antibody post, purity just can reach more than 95%; And no matter present home-made monoclonal antibody post in output and qualitatively, all can not satisfy producer's needs, need spend a large amount of funds imports, and production cost is very high.
[summary of the invention]
In order to overcome above-mentioned defective, the present invention adopts the yeast secreted expression system to replace the inclusion bodies of colibacillus expression system, and target protein α-1a Interferon, rabbit does not need renaturation, and its biological specific activity can reach 6.0 * 10
8Unit/milligram albumen, toxic side effect is low; In purge process, the monoclonal antibody post of value on demand costliness not can extract from fermented liquid and obtains purity and reach target protein α-1a Interferon, rabbit more than 95%, has reduced production cost.
The construction process of α-1a Interferon, rabbit Yeast recombinant strain is: the GAP promotor/α-site, factor signal peptide downstream that will clone the α-1a interferon gene insertion pGAPZ α-A that modifies, Ste13 site (Glu-Ala-Glu-Ala) and atg start codon ATG after deletion Kex2 (Lys-Arg) site are built into α-1a interferon gene secreted expression carrier; Utilize the method for the Pichia EasyComp Transformation Kit of Australian Invitrogen company to make improvements, with the bacterial strain GS115 of α-1a interferon gene secreted expression carrier conversion pichia (Pichia pastoris), be built into Yeast engineering bacterium strain--the IFN α-1a/pGAPZ α-A/GS115 of secretion type expression α-1a Interferon, rabbit; Analyze and biological specific activity mensuration by antibiotic-screening, SDS-PAGE, obtain the target Yeast recombinant strain.
The expression amount of above-mentioned Yeast recombinant strain target protein α-1a Interferon, rabbit is the 50-60% that target protein accounts for the secretion total protein, and specific activity is 1.08 * 10
9Unit/milligram albumen; The immunogenicity that target protein α-1a Interferon, rabbit has with natural α-the 1a Interferon, rabbit is identical.It is to be integrated in the genome form that this engineering strain is accepted foreign gene, this and intestinal bacteria, the outer plasmid expression system of the independent genome of yeast saccharomyces cerevisiae has marked difference, so this engineering strain is than intestinal bacteria, yeast saccharomyces cerevisiae is stable, be difficult for taking place foreign gene and lose phenomenon, in case with engineering bacteria as the sample template, pass through PCR, the positive strain that technical evaluation such as molecular hybridization choose must be true and reliable, and the direct expression-secretion of its objective expression product α-1a is in nutrient solution, therefore the biological activity that detects its expressing quantity and target product is very simple and easy, and this needs renaturation-much superior than coli expression system-expression product; In addition, yeast is a kind of simple eukaryote, so it expresses the post-treatment mode class like higher eucaryote, so the gene product of expressing with it not only has the identical biological activity of natural product, and low toxic side effect, the product tooling cost is low, and suitability is wider.
The purification process of α-1a Interferon, rabbit is: utilize the high product expression amount, the active Yeast recombinant strain of high product that obtain to ferment, centrifugal collection supernatant liquor is regulated pH with acetic acid, cross positively charged ion chromatography post, collect the target elution peak, add ammonium sulfate to muddy slightly, the centrifuging and taking supernatant liquor, cross the hydrophobic chromatography post, collect the target elution peak, cross the anion chromatography post, collect the target elution peak, cross the Sephacryl molecular sieve chromatography, collect target peak, obtain α-1a Interferon, rabbit.
The purification process of α provided by the invention-1a Interferon, rabbit has shortened the purifying time, does not need expensive monoclonal antibody post just can obtain purity greater than α-1a Interferon, rabbit stoste of 95%, has reduced cost, uses good economic benefit in industrial production.
[description of drawings]
Accompanying drawing is α-1a interferon expression vector construction figure.
PGAPZ α-A/IFN α-1a expression vector molecular size is 3.6kb
PGAPZ α-A carrier structure is:
Phosphoglycerate dehydrogenase gene promoter region: 1-483bp
Phosphoglycerate dehydrogenase gene promoter primer sites: 455-476bp
α-mating factor secretion signal peptide sequence: 493-759bp
α-mating factor secreting signal peptide primer sites: 696-716bp
Carrier multiple clone site: 760-828bp
Myc antigenic determinant bag: 827-856bp
Poly Histidine bag: 872-889bp
3 '-alcohol oxidase, 1 gene primer site: 974-994bp
Alcohol oxidase 1 Transcription Termination zone: 893-1233bp
Transcriptional elongation factor 1 promoter region: 1234-1644bp
Synthetic prokaryotic promoter: 1645-1712bp
Streptomycete zeocin resistant gene is read frame: 1713-2087bp
Cytopigment synthetase 1 Transcription Termination zone: 2088-2405bp
Intestinal bacteria replicon 1 (deriving from the pUC carrier): 2416-3089bp
[embodiment]
Introduce the present invention in detail in the structure of α-1a Interferon, rabbit recombination yeast engineering strain and the concrete application in α-1a Interferon, rabbit purifying process below in conjunction with embodiment.
Embodiment 1
One, the structure of IFN α-1a Interferon, rabbit Yeast engineering bacteria
(1) material:
1.IFN α-1a gene
2.pGAPZ α-A, P.pastoris Strain GS115 (his4) available from
Australia Invitrogen company.
(2) method:
1. gene PCR amplification:
(1) design of primers: in 5 ' end primer, delete Kex2 (Lys-Arg) site
Afterwards Ste13 site (Glu-Ala-Glu-Ala) and atg start codon ATG.
P1-5 ' G
CTCGAGAAAAGA
ATGTGTGATCTGCCTCAAACC3 ' (" ATG " is deleted)
Xho I Lys-Arg (Kex2 site)
P2-5’G
TCTAGATCATTCCTTACTTCTTAAACT3’
XbaI
(2) thermal cycling: 95 ℃, 5 '; 95 ℃, 30 " → 49 ℃, 30 " → 72 ℃, 60 " 72 ℃, 30 circulations of 10 ' amplification.
2.PCR amplified production reclaims and the clone:
(1) IFN α-1a gene obtains the DNA band of about 521bp behind the amplification electrophoresis;
(2) the PCR product high purity test kit of producing with German Bao Ling Man reclaims target fragment and carries out the T-Vector clone.
3. gene sequencing: the ABI 377A automatic dna sequencer that adopts U.S. PE company to produce carries out dna sequence analysis.
4. yeast secretion type expression vector construction: adopt gene clone technology with α-1a interferon gene by the Xho I/Xba I site that XhoI/XbaI inserts GAP promotor/α-factor signal peptide downstream of pGAPZ α-A, be built into the secretor type Yeast expression carrier that contains α-factor signal peptide; Expression vector transforms GS115 (his4): the method for PichiaEasyComp Transformation Kit (Cat.No.K1730-01) through making improvements slightly of utilizing Australian Invitrogen company to produce carried out.Concrete operations are as follows: the single bacterium colony of (1) picking pichia (Pichia pastoris) GS115, at 30 ℃, under 300 rev/mins of conditions with YPD+Zeocin100 mg/litre substratum shaking culture to OD600=1.3-1.5; Get in 0.1-0.5 milliliter bacterium liquid to the 50 milliliter same substratum shaking culture to OD600=6-8, under 5000 rev/mins, 4 ℃ conditions centrifugal 5 minutes, remove supernatant liquor, resuspended with 10 ml soln I, make competent cell; (2) get 100 microlitre competence, add the linearizing α of 5-10 microlitre-1a Interferon, rabbit recombinant expression vector, add 400 ml soln II again, cultivated 1 hour for 28 ℃ behind the mixing, add 1 milliliter of YPD, cultivated 1 hour for 30 ℃; (3) with culture under 5000 rev/mins, 4 ℃ conditions centrifugal 15 minutes, remove supernatant, resuspended with 200 ml soln III, coating YPD+Zeocin100 mg/litre flat board was cultivated 24-36 hour, and was produced single bacterium colony for 28-30 ℃.
5. the screening of high expression level Yeast engineering bacterium strain: behind Zeocin antibiotic-screening acquisition positive strain, extract the engineering bacteria genomic dna, the 520bp dna fragmentation of DiG Labelling and Detection Kit mark α-1a interferon gene of further making pcr analysis with primer P1/P2 and producing with German Bao Ling company is a probe, carry out technical evaluation such as Southern blotting and filter out positive strain, again with the IFN α-1a/pGAPZ α-A/GS115 engineering strain of SDS-PAGE screening high expression level target protein.
Embodiment 2
The purification process of α-1a Interferon, rabbit: make up α-1a Interferon, rabbit Yeast engineering bacteria and (behind the IFN α-1a/pGAPZ α-A/GS115), preserve bacterial classifications for-80 ℃.Before the fermentation, inoculation is dull and stereotyped, make actication of culture, in YPD+Zeocin100 mg/litre substratum, inoculate single bacterium colony fermentation 72 hours, centrifugal collection fermented supernatant fluid, regulate pH4.0-5.0 with acetic acid, cross CM Sepharose column chromatography, collect 0.4 mol sodium-chlor elution peak, add ammonium sulfate to 30%, the centrifuging and taking supernatant liquor, cross the PhenylSepharose column chromatography, collect 10% ammonium sulfate elution peak, cross DEAE Sepharose column chromatography, collect 0.1 mol sodium-chlor elution peak, cross Sephacryl S-200 column chromatography, collect protein peak, obtain purity greater than α-1a Interferon, rabbit stoste of 95%.
Claims (2)
1, a kind of Yeast recombinant strain, it is characterized in that α-1a interferon gene of clone's modification is inserted GAP promotor/α-site, factor signal peptide downstream of pGAPZ α-A, Ste13 site (Glu-Ala-Glu-Ala) and atg start codon ATG after deletion Kex2 (Lys-Arg) site, be built into α-1a interferon gene secreted expression carrier IFN α-1a/pGAPZ α-A, change the bacterial strain GS115 of pichia (Pichiapastoris) over to, be built into the Yeast recombinant strain IFN α-1a/pGAPZ α-A/GS115 of secretor type α-1a Interferon, rabbit.
2, the purification process of a kind of α-1a Interferon, rabbit, it is characterized in that directly from secretor type α-1a Interferon, rabbit Yeast engineering bacterium strain (separation and purification α-1a Interferon, rabbit the fermented liquid of IFN α-1a/pGAPZ α-A/GS115): centrifugal collection fermented supernatant fluid, regulate pH with acetic acid, cross the cation-exchange chromatography post, collect the target elution peak, add ammonium sulfate to muddy slightly, the centrifuging and taking supernatant liquor, cross the hydrophobic chromatography post, collect the target elution peak, cross the anion chromatography post, collect the target elution peak, cross the Sephacryl molecular sieve chromatography, collect target peak, obtain α-1a Interferon, rabbit.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02108973 CN1233816C (en) | 2002-04-16 | 2002-04-16 | Recombinant yeast strain and IFN alpha-la interferon purifying process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02108973 CN1233816C (en) | 2002-04-16 | 2002-04-16 | Recombinant yeast strain and IFN alpha-la interferon purifying process |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1548525A true CN1548525A (en) | 2004-11-24 |
CN1233816C CN1233816C (en) | 2005-12-28 |
Family
ID=34318894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02108973 Expired - Fee Related CN1233816C (en) | 2002-04-16 | 2002-04-16 | Recombinant yeast strain and IFN alpha-la interferon purifying process |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1233816C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102277374A (en) * | 2011-07-27 | 2011-12-14 | 浙江诺倍威生物技术有限公司 | Preparation and application of genetic engineering subunit vaccine for infectious bursal disease |
CN102796758A (en) * | 2012-08-06 | 2012-11-28 | 成都乾坤动物药业有限公司 | Recombinant porcine alpha interferon and application thereof in preparing medicines for treating Porcine cytomegalovirus (PCMV) |
CN101501209B (en) * | 2006-06-21 | 2013-06-05 | 百奥勤有限公司 | A method of producing biologically active polypeptide having insulinotropic activity |
CN107033233A (en) * | 2008-01-18 | 2017-08-11 | 弗·哈夫曼-拉罗切有限公司 | Purification of not-glycosylated polypeptides |
-
2002
- 2002-04-16 CN CN 02108973 patent/CN1233816C/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101501209B (en) * | 2006-06-21 | 2013-06-05 | 百奥勤有限公司 | A method of producing biologically active polypeptide having insulinotropic activity |
CN107033233A (en) * | 2008-01-18 | 2017-08-11 | 弗·哈夫曼-拉罗切有限公司 | Purification of not-glycosylated polypeptides |
CN102277374A (en) * | 2011-07-27 | 2011-12-14 | 浙江诺倍威生物技术有限公司 | Preparation and application of genetic engineering subunit vaccine for infectious bursal disease |
CN102277374B (en) * | 2011-07-27 | 2013-04-17 | 浙江诺倍威生物技术有限公司 | Preparation and application of genetic engineering subunit vaccine for infectious bursal disease |
CN102796758A (en) * | 2012-08-06 | 2012-11-28 | 成都乾坤动物药业有限公司 | Recombinant porcine alpha interferon and application thereof in preparing medicines for treating Porcine cytomegalovirus (PCMV) |
Also Published As
Publication number | Publication date |
---|---|
CN1233816C (en) | 2005-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Klein et al. | Alleviation of glucose repression of maltose metabolism by MIG1 disruption in Saccharomyces cerevisiae | |
CN102127512A (en) | Saccharomyces cerevisiae engineering bacterium capable of fermenting xylose | |
CN101886048B (en) | Lactic acid-producing engineering bacteria, constructing method thereof and application thereof | |
Villatte et al. | Expression level of heterologous proteins in Pichia pastoris is influenced by flask design | |
CN1699550A (en) | High density fermentation method for GS115/PFK-K5 | |
CN1233816C (en) | Recombinant yeast strain and IFN alpha-la interferon purifying process | |
CN101665798B (en) | Method for preparing recombinant human serum albumin and interferon alpha fusion protein | |
CN1238492C (en) | Yeast recombinant strain and IFN alpha-2b interferon purifying method | |
CN101613707B (en) | Method for producing glutathione by use of metabolic engineering bacteria | |
CN1916024A (en) | Constructing mutant sequence of high relative quick alphd-2b interferon, expression plasmid of yeast, strain filtration, and purification method | |
CN111378584B (en) | Lipase production strain and application thereof | |
CN1824781A (en) | Method for producing high specific activity HuG CSF yeast expression carrier, high production strain and HuG-CSF | |
CN101285045B (en) | Recombined kluyveromyces, construction method and applications thereof | |
CN106701605A (en) | Transgenic engineering saccharomyces cerevisiae SF4 for efficiently fermenting ethanol using xylose | |
CN102559730A (en) | Method for increasing expression of CP4-EPSPS in Hansenula polymorpha | |
CN1487086A (en) | Purification method of recombinant yeast strain and rhGM-CSF to express human granulocyte-macrophage colony stimulating factor | |
CN103088434B (en) | Construction method and application of Pichia stipitis large-fragment DNA (deoxyribonucleic acid) genome library | |
CN1062309C (en) | Phytase and the clone and expression of its gene | |
CN102533841B (en) | Method for increasing expression of bacillus thuringiensis(Bt) insecticidalcrystalprotein in hansenula polymorpha | |
CN100340662C (en) | High specific activity phytase gene and its efficient expression | |
CN114921354B (en) | Engineering strain for producing cordycepin and derivative 3' -deoxyinosine thereof as well as preparation method and application thereof | |
KR20110115923A (en) | Yeast expressing glucoamylase and alpha-amylase and method for producing ethanol using the same | |
EP1813670A1 (en) | Process for producing cohesive alcohol fermentation yeast and cohesive alcohol fermentation yeast | |
Roberts et al. | Production of 15 N-labelled hen egg white lysozyme using Aspergillus niger | |
CN118580980A (en) | Recombinant engineering bacterium for preparing recombinant human albumin and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Liang Guodong Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice |
Addressee: Hailiang Biological High-Tech. Co., Ltd., Hainan Document name: Notification of Termination of Patent Right |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051228 Termination date: 20100416 |